Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib - PubMed (original) (raw)
Case Reports
Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib
Norbert Frickhofen et al. Ann Hematol. 2004 Jul.
Abstract
Many cases of hypereosinophilia, formerly classified as hypereosinophilic syndrome, can now be characterized as chronic eosinophilic leukemia (CEL) based on the demonstration of characteristic genetic markers indicating clonality of hematopoiesis. Here we report on a 33-year-old male patient with central nervous system manifestations of CEL and an excellent response to low-dose imatinib (Glivec). Molecular analysis demonstrated a constitutive activation of the platelet-derived growth factor receptor-alpha (PDGFR-A) as the mechanism of responsiveness to imatinib.
Similar articles
- Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.
Martinelli G, Malagola M, Ottaviani E, Rosti G, Trabacchi E, Baccarani M. Martinelli G, et al. Haematologica. 2004 Feb;89(2):236-7. Haematologica. 2004. PMID: 15003901 No abstract available. - FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B, Chase A, Starza RL, Beacci D, Rosti V, Gallì A, Specchia G, Martelli MF, Vandenberghe P, Cools J, Jones AV, Cross NC, Marynen P, Mecucci C. Crescenzi B, et al. Leukemia. 2007 Mar;21(3):397-402. doi: 10.1038/sj.leu.2404510. Epub 2007 Jan 11. Leukemia. 2007. PMID: 17215855 - FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.
Gilliland G, Cools J, Stover EH, Wlodarska I, Marynen P. Gilliland G, et al. Hematol J. 2004;5 Suppl 3:S133-7. doi: 10.1038/sj.thj.6200439. Hematol J. 2004. PMID: 15190295 Review. No abstract available. - Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C, Fabarius A, Schnittger S, Grimwade D, Cross NC, Hehlmann R, Hochhaus A, Reiter A. Metzgeroth G, et al. Br J Haematol. 2008 Dec;143(5):707-15. doi: 10.1111/j.1365-2141.2008.07294.x. Epub 2008 Oct 17. Br J Haematol. 2008. PMID: 18950453 Clinical Trial. - FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
Cools J. Cools J. Verh K Acad Geneeskd Belg. 2005;67(3):169-76. Verh K Acad Geneeskd Belg. 2005. PMID: 16089297 Review.
Cited by
- A pan-cancer analysis of the core pre-mRNA 3' end processing factors, and their association with prognosis, tumor microenvironment, and potential targets.
Li X, Che Y, Wang X, Zhu Y. Li X, et al. Sci Rep. 2024 Jul 29;14(1):17428. doi: 10.1038/s41598-024-57402-6. Sci Rep. 2024. PMID: 39075070 Free PMC article. - Literature reviews of stroke with hypereosinophilic syndrome.
Ono R, Iwahana T, Kato H, Okada S, Kobayashi Y. Ono R, et al. Int J Cardiol Heart Vasc. 2021 Nov 25;37:100915. doi: 10.1016/j.ijcha.2021.100915. eCollection 2021 Dec. Int J Cardiol Heart Vasc. 2021. PMID: 34888412 Free PMC article. Review. - Analysing the eosinophil cationic protein--a clue to the function of the eosinophil granulocyte.
Bystrom J, Amin K, Bishop-Bailey D. Bystrom J, et al. Respir Res. 2011 Jan 14;12(1):10. doi: 10.1186/1465-9921-12-10. Respir Res. 2011. PMID: 21235798 Free PMC article. Review. - Chronic eosinophilic leukemia with the FIP1L1-PDGFRalpha fusion gene in a patient with a history of combination chemotherapy.
Tanaka Y, Kurata M, Togami K, Fujita H, Watanabe N, Matsushita A, Maeda A, Nagai K, Sada A, Matsui T, Takahashi T. Tanaka Y, et al. Int J Hematol. 2006 Feb;83(2):152-5. doi: 10.1532/IJH97.05048. Int J Hematol. 2006. PMID: 16513534 - Response to imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome associated with cyclic eosinophil oscillations.
Imashuku S, Kakazu N, Ueda I, Morimoto A, Harada H, Teramura T, Tamura S, Fukushima-Nakase Y, Kuroda H. Imashuku S, et al. Int J Hematol. 2005 May;81(4):310-4. doi: 10.1532/IJH97.04185. Int J Hematol. 2005. PMID: 15914361
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous